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ABSTRACT 
Most vaccines today are liquid formulations for parental administration. However, there are several 
drawbacks connected to these vaccines. Since injectable vaccines mainly induce systemic immune 
responses, they are usually not effective against many important pathogens that affect mucosal surfaces. 
Furthermore, liquid injectable vaccines need medical personnel for the administration, require cold chain 
maintenance and occupy large cargo sizes, which all are negative factors especially for vaccine use in 
developing countries. Solid and preferably mucoadhesive vaccine formulations that are administered via 
mucosal surfaces may overcome many of these problems. The aim of this thesis was therefore to 
investigate the design of such formulations with special emphasis on the influence of excipients on 
i) formulation-related properties such as mucoadhesion and antigen release and ii) antigen-functionality 
preservation during freeze-dying. 
 
In the first part of the thesis mechanistic and immunological investigations using mucoadhesive 
hydrophilic matrix tablets as potential formulations for sublingual immunization were performed. The 
effect of osmotic pressure differences on the adhesiveness of hydrophilic swelling matrix tablets was 
investigated with a model where the osmotic pressure difference could be tuned with different 
concentrations of additives. It was found that a decrease in the osmotic pressure difference resulted in a 
decrease in the adhesive force, i.e. the force required to detach the tablet from a wet surface. Release of 
the model antigen ovalbumin from hydrophilic matrix tablets providing an extended release and from a 
fast releasing formulation was characterized. The Bradford Assay used for the protein quantification was 
found to be disturbed by the hydrophilic polymer Carbopol® and a correction method was established. 
Sublingual immunizations in BALB/c mice indicated a poor potential of all extended release tablets to 
evoke intestinal immune responses, whereas an immediate release tablet formulation resulted in high 
antibody titres. Thus it was concluded that the latter formulation type should be preferred in sublingual 
immunization. In the second part of the thesis the stabilizing potential of different excipients during 
freeze-drying was tested using killed whole-cell Vibrio cholerae bacteria as a model vaccine for 
pathogens causing enteric infections. Sucrose showed great potential to avoid bacterial aggregation, 
preserve important antigen structures and maintained the immunogenicity of the bacteria. The addition of 
sucrose proved also useful for preparing a fully immunogenic formulation of the commercial oral cholera 
vaccine DukoralTM with regard to both antibacterial and antitoxic antibodies. 
 
 
Keywords: mucosal vaccination, sublingual vaccine tablet, mucoadhesion, osmotic pressure, hydrophilic 
matrix tablets, Bradford Assay, protein release, Vibrio cholerae, freeze-drying 
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 “Coming together is the beginning.  
Keeping together is progress.  
Working together is success.” 
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Chapter 1 
INTRODUCTION 
 
Human disease is as old as human life. Today many diseases can be treated 
with medicines and in many cases we are even able to prevent the population 
from specific diseases by the use of vaccinations. The term vaccination (Latin: 
vacca = cow) dates from the first documented immunization studies in 1796 
when the English physician Edward Jenner tested the use of the relatively 
benign cowpox virus to provide protection against the related and deadly 
smallpox virus [1]. His experiments led to the discovery that protection against 
specific diseases can be achieved by exposing the human being to the causative 
or a related agent for the disease [2]. From then on, the development and use of 
various vaccines has led to the protection of children and adults from 
previously lethal diseases. Today the worldwide use of vaccines is considered 
to be the most effective strategy to prevent, control and even eradicate 
infectious diseases. One successful example of the latter is the global 
eradication of smallpox, which was diagnosed the last time in 1978 and was 
announced to be eradicated in 1980 by the World Health Organization (WHO) 
[1]. 
 
Today there are about 40 vaccines on the market and most of them are liquid 
injectable vaccines. They often provide protection against specific diseases 
over several years or even long-life. So why design solid formulations for 
mucosal vaccination, i.e. vaccine administration via mucosal surfaces? People 
still die and fall ill from a variety of diseases although preventive vaccines 
against these diseases exist and for many diseases no effective vaccines exist at 
all. One main reason for the latter is that many of these diseases are caused by 
infections that start from or affect mucosal surfaces, such as the gastrointestinal 
tract, respiratory or genital tract. Injectable vaccines elicit systemic immune 
responses and may be effective at mucosal surfaces that are to some extent 
permeable for serum-derived antibodies. A mucosal vaccination seems though 
critical for the protection against infections at mucosal surfaces that are 
impermeable to antibodies, such as the gastrointestinal tract. An administration 
of the vaccine via a mucosal surface would instead stimulate the mucosal 
immune system which protects the different mucosal surfaces and thereby also 
the body interior. Besides immunological aspects, the injection of a vaccine is 
painful and includes a risk for the transmission of infections. Furthermore, the 
often high manufacturing costs, voluminous package sizes as well as cold chain 
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requirements of liquid injectable formulations cause high health care costs and 
impede distribution and storage, especially in developing countries, where the 
need for medical personnel for the administration is a further hindrance. 
Considering all these aspects, solid formulations for mucosal administration 
could be a beneficial alternative to meet all these challenges. Solid vaccine 
formulations for mucosal administration could thus provide several benefits to 
overcome the mentioned challenges. Pathogens might already be stopped at 
their portal of entry by the mucosal immune defence. Smaller package sizes 
and probably better stability properties of a solid formulation would 
furthermore facilitate transport, distribution and storage and thus the use of the 
vaccine in mass vaccination campaigns, even in developing countries. The 
latter is of course not only an advantage for mucosal vaccines but also for 
injectable ones.  
 
All things considered, it is highly probable that infections by mucosal 
pathogens, especially those affecting the gastrointestinal tract, can be controlled 
in all parts of the world if effective mucosal vaccines that are appropriately 
designed and formulated can be developed. This interdisciplinary work aims to 
combine the benefits of mucosal immunization and of solid state dosage forms 
and deals with different issues concerning the influence of excipients in the 
formulation design.  
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Chapter 2 
AIMS OF THE THESIS 
 
In the design of mucosal vaccines it is important to consider crucial 
formulation properties in relation to the required functionality and efficacy of 
the dosage form. The intention of this thesis was to investigate the influence of 
excipients in the design of solid state vaccine formulations for mucosal 
administration. The following areas, where excipients are important, were 
investigated: mucoadhesion mechanism and mucoadhesive properties, protein 
analysis in the presence of pharmaceutical excipients, controlled protein release 
from sublingual tablets and the effect on the immune response in mice, and 
freeze-drying of killed whole-cell bacteria. Many of these factors have been 
discussed in the literature in different contents whereas others have not been 
investigated at all so that more detailed and also more applied investigations 
are required.  
 
The specific aims of the papers included in this thesis were: 
 
 To study the correlation between water mass transport due to osmotic 
pressure differences and mucoadhesion of dry hydrophilic polymer tablets 
in order to gain more knowledge about the factors that influence 
mucoadhesion (Paper I). 
 To critically examine the commonly used Bradford Method for protein 
concentration determination in the presence of different pharmaceutically 
relevant excipients (Paper II). 
 To investigate the influence of protein release rate from tablets on the 
elicited immune responses after sublingual immunization (Paper III). 
 To compare different excipient conditions during freeze-drying of bacteria 
with respect to the ability to prevent bacterial aggregation, maintain 
important morphological structures and preserve the oral immunogenicity 
of freeze-dried bacterial vaccines (Paper IV). 
 
The next two chapters will give a background to these different topics in order 
to provide an easier understanding of the different studies and results. 
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Chapter 3 
MUCOSAL VACCINATION 
 
‘Vaccination’ or ‘active immunization’ involves the administration of an 
antigen or antigenic material that triggers the development of immunologic 
defence against a future exposure to this antigen [3]. An antigen (short for 
antibody generator), sometimes also termed immunogen, is a substance that 
binds to specific immune receptors and is recognized by the immune system as 
foreign [4]. Once recognized as foreign, the immune system, which includes 
tissues, cells and molecules, can elicit an immune response to protect the host 
against the invading pathogen. After such a response the immune system is 
trained to defend itself against the pathogen, i.e. it can recognize and efficiently 
respond to subsequent invasions by the same or related pathogens. This ability 
is called immunological memory and forms the basis of preventative vaccines. 
Training the immune system often requires repeated exposure to the antigen 
and hence the use of booster doses is required in many vaccine regimens. 
 
Although numerous effective vaccines against systemic infections are 
available, the need for the development of vaccines against pathogens which 
cause infections of or via mucosal tissues still remains. Most often the mucosal 
route of vaccination is necessary in order to stimulate the local mucosal 
immune system. A brief description of the mucosal immune system and 
different mucosal sites for vaccination are given in the following chapters. 
 
3.1 The mucosal immune system 
In the human body specific mucosae line the aerodigestive and urogenital 
tracts, the eye conjunctiva, the inner ear and the ducts of all exocrine glands. 
The totally 400 m2 of mucosal surfaces are in contact with the external 
environment and often exposed to external microbes and pathogens. Several 
mechanical and chemical cleaning mechanisms work together with a 
specialized mucosal innate and adaptive immune system in order to provide 
protection against the colonization at mucosal tissues and the invasion into the 
body interior by external pathogens and foreign proteins [5]. 
 
Evidence for a common mucosal immune system was already mentioned in 
1979 by McDermott and Bienenstock [6]. As extensively discussed and 
reviewed elsewhere [7, 8], it is today known that lymph nodes draining the 
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mucosal tissues and aggregates of lymphocytes, so-called mucosa-associated 
lymphoid tissues (MALT), located below the mucosal surfaces form a highly 
compartmentalized mucosal immune system that functions independently from 
the systemic immune system and serves as mucosal inductive site for the 
initiation of immune responses. Like the systemic lymphoid tissues the MALT 
is populated by different types of lymphocytes, such as B- and T-lymphocytes 
(B- and T-cells). The MALT comprises about 80% of all immunoglobulin-
producing cells in the human body and its main sites are the gut-associated 
lymphoid tissues (GALT), which include specialized structures called Peyer’s 
patches in the small intestine, the bronchial-associated lymphoid tissues 
(BALT) and the nasal-associated lymphoid tissue (NALT) [9-11]. Their 
common denominator is that they all serve as mucosal inductive sites for the 
initiation of immune responses. 
 
Antigens that enter our body are either taken up by absorptive epithelial cells or 
through specialized epithelial cells mechanisms. An example of a specialized 
uptake mechanism is the transport of antigens in the gut, where specialized 
microfold cells (M-cells) discovered in 1974 by Owen and Jones [12] line the 
Peyer’s patches and facilitate antigen transport across the epithelium [13]. 
Having been identified as “dangerous” the antigen is captured and processed by 
so called antigen-presenting cells (APCs) of the innate immune system, mainly 
dendritic cells (DCs), B lymphocytes (B cells) and macrophages [14]. They 
load peptide fragments into either major histocompatibility complex (MHC)-I 
or MHC-II molecules on their surface for display of the antigenic material to 
adjacent CD 4+ or CD 8+ T lymphocytes (T cells), depending on the type of 
antigen [14]. The activated mucosal lymphocytes, both B and T cells, then 
move through the lymphatic system and enter the systemic circulation to finally 
end up at specific mucosal sites where differentiation into either effector or 
memory cells takes place [15]. As a result of this adaptive immune response 
increased antigenic specificity and memory are obtained. Figure 1 illustrates 
possible mechanisms for the uptake and processing of an exogenous antigen at 
the sublingual mucosa. 
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Figure 1. Schematic drawing that illustrates the uptake and processing of exogenous antigens at the 
sublingual mucosa. When an exogenous antigen is identified as “dangerous” antigen-presenting cells 
(APCs), such as dendritic cells (DCs), are recruited to capture antigen (as indicated by the purple 
arrow). The APCs and probably also some free antigen migrate via the draining lymph to lymph nodes, 
where they become active APCs that stimulate T and B cells for immune responses. The activated T 
and B cells can subsequently via the lymph enter the systemic circulation and migrate to either mucosal 
effector sites or extramucosal sites. 
 
The dominant antibody type in external secretions, such as saliva or intestinal 
fluid, is IgA, mainly in the form of secretory IgA (SIgA). SIgA is a dimer of 
two monomeric IgA molecules that are covalently linked by a joining chain (J 
chain) molecule and non-covalently complexed with a so-called secretory 
component (SC) molecule produced by mucosal epithelial cells. The formation 
of this complex molecule can briefly be described as follows. The dimeric, or 
polymeric, IgA (pIgA) part is synthesized by plasma cells in the lamina propria 
of mucosal tissues. After binding to a transmembrane glycoprotein, called the 
polymeric immunoglobulin (pIg) receptor, on the basolateral side of the 
epithelial cells pIgA is transported by transcytosis to the apical side of the 
epithelium. There it is released from the cells into the mucosal secretions as 
final SIgA through a proteolytic cleavage of the transmembrane part of the pIg 
receptor leaving the rest of the receptor, the SC, associated with the pIgA [16]. 
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In the often protease rich mucosal secretions the protease resistance of the SC 
molecule allows SIgA to survive for a long time [17]. Numerous studies have 
provided evidence for the protective role of SIgA [18-22]. The different 
mechanisms of protection include the ability of SIgA to hinder pathogens from 
penetration through and adhesion to the mucosa [23, 24], inhibition of 
multiplication and colonization as well as penetration of pathogens across 
epithelia [25, 26], neutralization of their toxins [27] and enhancement of non-
specific defence mechanisms [28]. In addition, it has been found that SIgA can 
also limit the person-to-person transmission of pathogens [29]. 
 
3.2 Advantages of mucosal vaccination  
Mucosal vaccination has gained a lot of interest in the recent years [30-32]. The 
mucosal route of vaccination offers several advantages. The needle-free 
administration increases patient compliance, decreases the risk for blood-borne 
infections due to the injection and reduces health care costs due to the ease of 
administration which does not require specialists. All these factors are 
especially of advantage in low income countries.  
 
However, the main reason for using the mucosal route of immunization is the 
fact that, besides systemic immunity, the local mucosal immune system can 
also be stimulated which offers great possibilities as many infections are 
acquired at mucosal surfaces. Examples are gastrointestinal infections caused 
by Vibrio cholerae (V. cholerae), Salmonellae spp. or Shigella spp., respiratory 
infections caused by influenza virus or Mycoplasma pneumoniae or sexually 
transmitted genital infections caused by Chlamydia trachomatis or human 
immunodeficiency virus (HIV) [33]. For infections at mucosal sites with a 
good permeability for serum antibodies such as the lower respiratory tract and 
the female genital mucosae an injectable vaccine may still provide sufficient 
efficacy. However, when the infection occurs at a mucosal site with low or no 
antibody permeability to serum-derived antibodies that are induced upon 
parenteral immunization, a local mucosal administration of the antigen is most 
often crucial to achieve efficient protection. This is for example the case for 
gastrointestinal infections caused by V. cholerae or Enterotoxigenic 
Escherichia coli (ETEC) [33]. 
 
As recently reviewed by Holmgren and Czerkinsky [31], the effects after 
mucosal immunization are highly compartmentalized, even between regions 
within the same mucosal organ as for example the gastrointestinal tract. For 
example, oral immunization leads to considerable antibody levels in the 
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salivary glands, the stomach and the small intestine but elicits only poor 
responses in distal segments of the gut, whereas rectal immunization provokes 
the strongest local antibody responses in the rectum [34-36]. Since the mucosal 
tissues are interconnected via circulating lymphocytes, a local administration of 
vaccine may even initiate responses at other mucosal sites in the body [37]. 
However, the best response is thought to be induced at the mucosal site initially 
exposed to the antigen. Given the high degree of compartmentalization of the 
mucosal immune system, different factors have to be taken into account in 
order to select the appropriate route or maybe a combination of immunization 
routes when designing mucosal vaccines. Besides the most likely site of 
challenge where a protective immunity is desired, the advantages and 
disadvantages of the different administration sites also have to be considered. 
 
3.3 Choice of mucosal vaccination route 
The oral or nasal mucosa are traditional mucosal sites for the administration of 
vaccines, but also other mucosal routes such as the rectal, vaginal or 
transcutaneous and recently also the sublingual route have been investigated for 
inducing mucosal immunity. The objective of this thesis was not to study or 
compare different mucosal administration sites for vaccine delivery. 
Nonetheless, a brief comparison of the most common mucosal routes for 
immunization will be given since all investigations of my work were aimed for 
the development of improved mucosal vaccine delivery systems. 
 
Oral immunization can induce substantial immune responses in the 
gastrointestinal tract, but also in the mammary and salivary glands [36, 38-40]. 
One successful example of a licensed oral vaccine is the oral cholera vaccine 
(DukoralTM). However, it is a challenge to develop oral vaccines with sufficient 
efficacy. A main problem in oral immunization is the degradation and 
destruction of antigens by several enzymes present in the gastrointestinal tract 
as well as the acidic environment in the stomach so that delivery systems that 
can sufficiently protect the antigen are required. In developing countries the 
efficacy of oral vaccines is additionally restricted by chronic environmental 
enteropathy, especially in children, which causes disturbances in the digestion 
and malabsorption due to overgrowth of the intestinal flora and local 
inflammation [5]. 
 
The respiratory tract including the highly permeable nasal mucosa seems a 
natural target for vaccines against severe infectious diseases of the respiratory 
tract, such as influenza and pneumonia, since strong antibody responses can be 
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induced in the mucosae of the airways and in nasal secretions. More surprising, 
the nasal mucosa has also been found to evoke antibody responses in cervical 
and vaginal secretions, thus providing a potential for vaccines against sexually 
transmitted infections, e.g. HIV [41]. However, there are some disadvantages 
of nasal immunization that should be considered. The nasal cavity provides a 
large absorption area [42], but natural differences in membrane permeability or 
diseases affecting the mucosal surface, such as allergic rhinitis, can lead to a 
high variation in the antigen uptake and thus to differences in the effectiveness 
of nasally administered vaccines. The volume and thus the dose of antigen that 
can be sprayed into the nose at once is limited [43]. Furthermore, it is known 
that antigens and adjuvants can be translocated to the olfactory bulb of the 
brain upon intranasal administration [44]. This retrograde transport to the brain 
can of course be an advantage for drugs with a desired effect in the central 
nervous system, but it raises severe concerns about safety issues for human 
nasal vaccines. 
 
The sublingual mucosa, i.e. the mucosa under the tongue, has been studied for a 
long time and found to be advantageous as delivery route for low-molecular-
weight drugs due to its easy accessibility and fast uptake of the active 
pharmaceutical ingredient (API) into the bloodstream [45]. During the last 
decade, this route has also received increasing attention as a delivery site for 
mucosal vaccines and immunotherapeutics. Several studies with different 
antigens have shown the efficacy of sublingual immunization [46-51] and 
sublingual immunotherapy has been successfully investigated and used with 
increasing frequency in allergy treatment [52-56]. The sublingual mucosal 
epithelium in humans is comprised of a non-keratinized, stratified, squamous 
epithelium located on top of a basement membrane. This membrane forms the 
boundary to the underlying lamina propria, which contains of a dense network 
of dendritic-like cells that are responsible for antigen capturing, as well as 
numerous mononuclear leucocytes, whereas MALT is not present [48, 57]. An 
induction of both mucosal and systemic immune responses is possible after 
sublingual vaccination with an exceptionally broad dissemination of effector 
cells to different mucosal surfaces including the gastrointestinal and the 
respiratory tracts and most interestingly also the genital mucosa [47, 49-51]. 
Thus, sublingual vaccination may offer an alternative to the nasal or oral route 
of immunization with various advantages. Although the human sublingual 
epithelium is thicker than that of the nasal cavity and the surface area of the 
sublingual mucosa is smaller than in the nose [58, 59], antigens are quickly 
absorbed via the sublingual mucosa without passing through the 
gastrointestinal tract so that enzymatic degradation, as occurs in oral 
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administration, is avoided [45]. Unresponsiveness of oral vaccines connected to 
chronic environmental enteropathy which is a huge problem in children of 
developing countries might possibly be circumvented by sublingual 
immunization. Furthermore, in comparison with nasal vaccination, the 
production of convenient delivery systems for sublingual vaccine delivery is 
not as challenging. Tablets or mucoadhesive films can for example be given 
sublingually, whereas a special delivery device such as an aerosol dispenser is 
often required for nasal administration. Moreover, and importantly in 
comparison to nasal immunization, sublingually administered antigens or 
adjuvants have not been found to be translocated to the olfactory bulb in the 
brain [60]. Thus, sublingual vaccines seem to be safer than intranasal vaccines 
from that point of view.  
 
Taken everything into consideration, the sublingual route of immunization 
provides several advantages over traditional mucosal routes and has therefore 
become an attractive site for vaccination studies against different infections in 
the gastrointestinal tract, respiratory and female reproductive tract, although its 
effectiveness in humans remains to be determined. In this work, the effect of 
protein release rates in correlation to the immune response was studied for this 
vaccination route in order to gain knowledge about suitable tablet 
characteristics for potential sublingual vaccine candidates. The oral route was 
used in Paper IV to study the immunogenicity of freeze-dried whole-cell V. 
cholerae bacteria since a commercially available oral vaccine based on these 
bacteria was used as a model system.  
 
3.4 Challenges in mucosal immunization 
Despite the various advantages of mucosal immunization mentioned before, the 
question still crops up why there are only a few mucosal vaccines approved for 
human use on the market compared to over 30 registered injectable vaccines? 
Of course, the evaluation of the immunogenicity of a mucosal vaccine in 
humans is not as simple as for injectable ones since it is considerably easier to 
measure the systemic antibody response in the blood than to measure the 
mucosal immune response. However, a major problem is that proteins often 
behave as poor immunogens when delivered to mucosal surfaces. For a 
significant immune response, the antigen has to be exposed to the immune 
system in a sufficient amount, often much higher than needed in parenteral 
administration. After administration to a mucus membrane, the antigen has 
therefore to be transported across the epithelium to come into contact with 
APCs. The production of mucus as a natural protection barrier to keep 
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pathogens away from the epithelium, as well as dilution due to salivation and 
mechanical stress in the oral cavity, can however limit antigen exposure and 
uptake and thus antigen accessibility for the immune [61]. In addition, the high 
molecular weight of proteins is often a limiting factor, resulting in only small 
amounts of antigen crossing the intact mucosa to reach the immune competent 
cells [62]. In mucosal tissues with MALTs, this is less of a problem as 
specialized mechanisms are often available to deliver the antigen for example 
via transcytosis to APCs and lymphocytes located at the basolateral side [14]. 
However, even here the exposure is limited since only small areas are 
associated with these specialized regions. A problem which occurs more or less 
in all cases of mucosal delivery is the degradation of the antigen prior to or 
during the absorption process by mucosal and luminal enzymes. This is 
particularly a problem in the gastrointestinal tract, especially when the protein 
is delivered unprotected [63]. A further difficulty lies in the fact that many 
proteins, such as food proteins, are actively tolerated by the mucosal immune 
system [61]. Therefore, the co-administration of so called adjuvants is often 
necessary to activate APCs and/or other innate signalling pathways in the 
epithelial cells in order to enhance the immune response against the antigen. 
The development of safe and efficient adjuvants and appropriate delivery 
systems that can provide protection, increase antigen uptake and enhance the 
immune response to an antigen will thus be necessary in order to overcome the 
challenges one has to deal with in mucosal vaccination.  
 
3.5 Oral killed whole-cell cholera vaccine as model for 
mucosal vaccines against enteric diseases 
Enteric infections that cause billions of disease episodes and millions of deaths 
every year in developing countries, especially in children, and that are also a 
common cause of illness in travellers to affected regions continue to be a global 
health problem [64]. Vaccines are only available against some of these diseases 
and there is a great need for the further development of mucosal vaccine 
formulations against the many different disease causing agents. Cholera is a 
typical example of an enteric disease for which a protective vaccine exists and 
where the use of a mucosal vaccine is most efficient since cholera is caused by 
a non-invasive pathogen that remains at the apical side of the mucosal epithelia 
in the gastrointestinal tract. In spite of the available vaccines against cholera, it 
still causes high morbidity and mortality in parts of the world and continues to 
be one of the main causes of diarrhoeal diseases in many developing countries 
where it is a significant negative factor for the economic development. Cholera 
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is endemic in over 50 countries, mainly in Asia and Africa and the prevalence 
of cholera shows no tendency to decrease. In 2011, a 85 % increase compared 
to 2010 was reported to the WHO, with a total of 589 854 cases worldwide 
including 7816 deaths [65]. Cholera is caused by the bacterium V. cholerae and 
in 98 % of all cases by a single serogroup (O1) and biotype (El Tor) [66]. 
Cholera is transmitted via the faecal-oral route. V. cholerae bacteria enter our 
body via contaminated water, which is particularly a problem in countries with 
poor sanitation and hygiene conditions, and via contaminated food, e.g. 
undercooked seafood [67]. The bacterium colonizes the mucosa in the upper 
part of the small intestine where it starts to produce the pathogenic cholera 
toxin (CT). The action of CT on the intestinal epithelium provokes severe and 
life-threatening watery diarrhoea. The rate of diarrhoea can often reach up to 
one liter per hour, thus causing acute dehydration [67].  
 
The first developed vaccines against cholera were killed injectable whole-cell 
vaccines that were used worldwide [68]. However, these vaccines were not 
cost-effective since they provided only limited and short-lived protection even 
after annual booster doses and the immunizations were associated with adverse 
reactions such as local inflammatory reactions [69]. For these reasons the 
WHO has long stopped recommending the use of these injectable cholera 
vaccines. Instead oral cholera vaccines (OCV) with stronger efficacy and 
negligible side effects have been developed. Until recently, the only 
commercially available mucosal cholera vaccine with a demonstrated efficacy 
of up to 90 % has been the OCV DukoralTM [68]. The vaccine is based on a 
killed whole-cell mixture of V. cholerae (three different strains that are 
inactivated by two different methods) combined with purified recombinant 
CTB and it has been shown that the protective efficacy is based on the local 
intestinal production of both antibacterial and antitoxic SIgA antibodies [70]. In 
2009 a second OCV was licensed that contains similar whole-cell bacterial 
components as the DukoralTM vaccine but lacks CTB. The immunogenicity of 
both V. cholerea and CTB can easily be estimated by different in vitro and in 
vivo methods. Due to the known efficacy of the DukoralTM vaccine and the fact 
that several tools for in vitro and in vivo evaluations are available, it was used 
as a model vaccine for the evaluation of excipients as stabilizers during freeze-
drying of killed whole-cell bacteria in Paper IV. Initial investigations were 
performed on formalin-killed V. cholerae O1 bacteria of the Inaba serotype 
(strain JS 1569), a derivative of the toxin-depleted oral vaccine strain CVD103 
that was used in a live-attenuated oral vaccine which is no longer produced 
[71]. The most promising freeze-drying conditions were then applied to the 
DukoralTM vaccine. 
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3.6 In vivo evaluation of mucosal vaccines 
3.6.1 Murine model for mucosal vaccination 
Within biomedical research animal testing is still the best proof-of-concept 
method prior to clinical trials and it is as important as clinical testing of new 
therapies before they are approved for widespread use on humans. Which 
animal model one choses depends on the goals of the study, robustness of the 
animal for the experiments, costs, ease of handling, the availability of 
immunological reagents as well as facilities for housing and how familiar the 
laboratory is with a specific species. In studies where a high number of animals 
are needed for the statistical outcome of the testing, mice are ideal animals. 
They have short life cycles, are inexpensive and relatively easy to purchase and 
maintain and are therefore extensively used for the discovery and 
manufacturing of new vaccines [72]. 
  
The majority of all animal studies on mucosal immunization have been 
performed using mice [73]. However, as with all animal models, there are some 
limitations connected to the murine model. When mice are used for 
investigations of sublingually administered antigens one has to consider that, in 
contrast to humans, the epithelial cells at the floor of the mouth are keratinized, 
so that the uptake of antigens might be different to humans [50]. In order to be 
able to immunize mice, they may need to be anaesthetized for a short time, 
which might also have an impact on the immune response. In Paper III and IV 
mucosal immunizations in female BALB/c mice were performed in order to 
evaluate the different formulations in vivo. All animals were used one week 
after delivery at the age of about 8 weeks and were marked individually prior to 
the experiments. For the administration of the test formulations all the mice 
were slightly anaesthetized. Booster immunizations were performed as 
described in the respective papers in order to achieve sufficient immune 
responses and to reduce the inter-mouse variability in responses.  
 
3.6.2 Cholera toxin as adjuvant in mucosal immunization 
As mentioned above, several antigens and pathogens evoke only weak adaptive 
immune responses upon mucosal administration, so that the use an adjuvant is 
necessary. CT produced by V. cholerae bacteria, which was identified over 50 
years ago by De [74] and Dutta et al. [75] as the toxic substance causing 
cholera disease, is, together with the closely related Escherichia coli heat-labile 
enterotoxin (LT), the best studied and most potent adjuvant known for use in 
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mucosal immunization. Both CT and LT have been shown in several animal 
models to strongly potentiate the immunogenicity of several antigens when co-
administered [76-79]. The most important effect is probably an increased 
antigen presentation by dendritic cells (DCs), macrophages and B cells [80]. 
However, the underlying mechanisms of CT adjuvanticity are still not fully 
understood.  
 
CT has a molecular mass of about 85 kDa and consists of a single active A-
subunit (CTA) which is non-covalently bound to a five-membered B-subunit 
ring (CTB) [81]. After binding of the CTB subunits to GM1 ganglioside 
receptors on the surface of intestinal epithelium cells, CT is endocytosed and 
dissociates into its subunits. Subsequently, the CTA subunit activates the 
adenylate-cyclase enzyme which leads to an increased production of 
intracellular adenosine monophosphate. This, in turn, leads to the secretion of 
electrolytes and water into the lumen of the small intestine causing diarrhoea 
and rapid dehydration, i.e. cholera disease [81-83]. Even just small quantities of 
CT are highly toxic in humans and cannot be used as adjuvant for human 
vaccines [84]. Therefore, several approaches to develop genetically modified 
derivatives with reduced or no toxic activity but retained mucosal adjuvant 
properties have been undertaken in many laboratories.  
 
In the sublingual immunizations in Paper III CT adjuvant was co-administered 
with the model soluble protein antigen ovalbumin (OVA) since CT has proven 
to induce strong antibody responses against sublingually delivered OVA [48]. 
Since the experiments were only aimed at understanding the general 
functionality for the development of sublingual tablets, the toxicity of CT in 
humans could be neglected.  
 
3.6.3 Sublingual immunizations 
For the investigations in Paper III on the effect of protein release in sublingual 
immunization the model protein ovalbumin (OVA) was incorporated in 
different tablet formulations. OVA is a phosphorylated glycoprotein made up 
of 385 amino acids with a molecular weight of 42.7 kDa [85] and is a 
commonly used model soluble protein antigen in immunology research for 
studies of immune response. Earlier studies have shown the ability of this 
model antigen to induce mucosal antibody responses in mice, both when 
administered alone or along with CT adjuvant [48]. 
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The administration of the sublingual tablets was carried out by holding the 
tongue of the slightly anaesthetized mice with a forceps with small plastic tubes 
on the tips and pressing the tablet with another forceps against the ventral side 
of the tongue. An anaesthesia with isofluorane leads to a reduced production of 
saliva in mice which was found to impede the mucoadhesion of the tablets. 
Therefore a subcutaneous dose of pilocarpine-HCl was co-administered which 
has been shown to stimulate mouse salivary secretion [86]. Since chewing can 
lead to an initial loosening of the tablet, food and water was not provided until 
30 minutes after administration. Each mouse was also kept in a cage with a 
black bottom so that spewed out tablets could be observed. The retention of 
pure Carbopol® tablets was tested in a group of 5 test mice which were 
anaesthetized a second time 2 hours after administration. The tongue of each 
mouse was carefully lifted to inspect the status of the tablet (Figure 2).  
 
 
Figure 2. Photograph of a C57/Bl6 mouse during the ocular inspection of a mucoadhesive tablet 
2 hours after sublingual administration. The arrow indicates the swollen tablet at the ventral side of the 
tongue. 
 
3.6.4 Peroral immunizations  
Since an oral killed whole-cell vaccine was used as the model vaccine in the 
work in Paper IV, peroral, or more specifically intragastric, immunizations 
were performed with all freeze-dried vaccine preparations to be compared with 
the original vaccine. The freeze-dried preparations were re-suspended in buffer 
prior to administration. The formulations were administered using special 
feeding needles with silicon tips that were inserted into the stomach under a 
light anaesthesia. In order to neutralize the acidic environment of the stomach 
all preparations were co-administered with a neutralizing sodium bicarbonate 
solution.  
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3.6.5 Analysis of immune responses 
Both systemic and mucosal immune responses are of interest for the evaluation 
of the immunogenicity of a vaccine. For the analysis of the systemic responses 
serum IgG and/or IgM antibody titres are usually determined in serum samples. 
For the estimation of mucosal immune responses IgA antibody titres are 
measured in the tissues chosen depending on the administration route and the 
type of disease. In Paper III and IV, blood samples for the final analysis of the 
systemic immune responses were taken from the subclavian vein of 
anaesthetized mice and the sera were analysed for IgG+IgM antibody levels. 
Since both sublingual and peroral immunization evokes strong immune 
responses in the gastrointestinal tract, intestinal IgA antibody responses were 
examined. In Paper III tissue extracts of the small intestine were prepared using 
a modified version of the perfusion-extraction technique [87]. In Paper IV 
supernatants from homogenized and centrifuged fecal pellets [88] as well as 
tissue extracts were used for the investigation of intestinal IgA levels.  
 
All samples were analyzed by enzyme-linked immuno-sorbent assays (ELISA). 
ELISA is the most commonly used biochemical technique in immunology to 
detect antibodies or antigen in a sample and is based on an antigen-antibody 
reaction followed by enzyme-coupling [89], as illustrated in Figure 3 for the 
commonly used “indirect” assay.  
 
 
Antigen
Primary antibody
Secondary antibody
Reaction with substrate and UV 
measurement
 
Figure 3. Illustration of the “indirect” ELISA method for the detection of antigen or antibody.  
 
In the “indirect” assay, which was mainly used in this work, antigen is adhered 
to a surface and a specific primary antibody to the antigen is then added. In 
Paper III and IV the antibody to be analyzed in the samples from the 
immunizations was added in this step. Then a second specific, enzyme-linked 
antibody is applied that can bind to the primary antibody and finally a substrate 
to the enzyme is added. The colour change of the substrate due to the reaction 
 -17- 
with the enzyme can be measured with a spectrophotometer and the detected 
absorbance can be directly correlated to the amount of primary antibody bound 
to the antigen. In order to be able to quantitatively determine the antibody 
amount in a sample, a standard curve of known primary antibody 
concentrations is included in the assay [89]. The systemic and mucosal 
antibody responses in all immunized mice in Papers III and IV were analyzed 
on microtiter plates by “indirect” ELISA as described in detail in the respective 
papers. 
 
 -18- 
Chapter 4 
SOLID DOSAGE FORMS FOR MUCOSAL 
VACCINATION 
 
The first chapters in this thesis highlight the benefits but also the challenges of 
mucosal immunization faced by immunologists and make clear that the design 
of suitable formulations is complex and of utmost importance in order to 
overcome some of the problems. So this begs the question as to what properties 
such a formulation should have and how we can use pharmaceutical excipients 
to design solid dosage forms that are suitable and effective in mucosal 
vaccination. The following chapters describe and explore different contents 
where excipients can be used and where it is essential to understand their role 
and impact during development and manufacturing. A background of the main 
areas of interest is given together with a description of the essential methods 
and materials of each study. More detailed experimental descriptions can be 
found in the respective papers.  
 
4.1 Use of excipients in solid state formulations 
Pharmaceutical formulations in the solid state can for example be powders, 
granules, capsules, films or tablets. All these formulations are normally 
prepared from mixtures of the API and so-called pharmaceutical excipients that 
help attain the desired properties. Tablets are the most common solid dosage 
form and comprise today about 40 % of all dosage forms on the market. They 
are easy and relatively cheap to produce and are often described as convenient 
for self-administration since they can easily be handled by the patient [90-92]. 
A tablet is prepared by compressing a powder where shape and size are 
controlled by the die and the punch used for compression. Even multiple-layer 
tablets can be compressed with the API in both or in one of the layers. After 
preparation, tablets can be coated with solutions of sugars or polymers. Such 
coatings can, for example, mask the taste of the API or can color the tablet for 
easier recognition and distinguishing, for example when several tablets have to 
be taken by a patient. The coating can even modify the release properties of the 
tablet. Especially important for normally sensitive antigenic material is the fact 
that the antigen can be protected in the tablet matrix from destructive 
influences in the environment during distribution and storage, such as 
humidity, and in the body after intake, such as enzymes or gastric acid [91].  
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Depending on the API, the administration site and the desired effect in the body 
different formulation aspects have to be taken into account where the use of the 
right excipients is essential. If the promising sublingual route is to be used for 
vaccination a solid vaccine might be easier to keep under the tongue than a 
solution or a gel, which is easily washed away or swallowed. The use of 
mucoadhesive excipients can here provide additional advantages. A tablet can 
be designed to release the API immediately or prolonged over a defined period 
of time. Furthermore, for the preparation of a solid vaccine formulation dried 
antigenic material needs to be produced. Since proteins and other biological 
materials often are labile to drying processes, the use of stabilizing excipients 
might be crucial. 
 
4.2 Mucoadhesive tablets 
4.2.1 Mechanism of mucoadhesion 
When a vaccine is to be administered via a mucosal surface, it can be helpful to 
keep the vaccine at the site of administration for a sufficient time, so that all 
antigenic material can be taken up and processed. Especially when the vaccine 
is given via the mucosal surfaces of the oral cavity, there is a risk that the 
vaccine is swallowed before all antigen is released and taken up. Here 
mucoadhesive agents can be used to prepare formulations that adhere to 
mucosal surfaces. A widely explored group of mucoadhesive agents that can be 
used in dry formulations like tablets are hydrophilic polymers including 
chitosan, Carbopol®, carboxymethylcellulose, hydroxypropyl- and 
hydroxypropyl methylcellulose [93]. These polymers contain a high number of 
hydrogen bond forming groups and the adhesive properties are initiated by 
applying moisture.  
 
The process of mucoadhesion is referred to as bioadhesive interactions with 
mucosal surfaces [94]. For the establishment of a mucoadhesive bond, close 
contact between the formulation and mucus is required. Different bonds are 
discussed to cause adhesion: ionic, covalent, hydrogen, van-der-Waals or 
hydrophobic bonds [95]. The detailed mechanisms behind mucoadhesion and 
factors influencing the strength of a mucoadhesive bond are still not completely 
understood and might vary depending on the in vivo situation and the type of 
formulation, but in all cases the adhesion process between a mucoadhesive 
material and a mucous membrane occurs in two steps [95]. The first one is the 
contact stage where a close contact is established and the second one is the 
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consolidation stage where different interactions strengthen the adhesive joint. 
Two main mechanisms are discussed in the literature: the interpenetration 
theory and the dehydration theory [95]. The interpenetration theory explains the 
mucoadhesion process on a macromolecular level. After contact and wetting of 
the mucoadhesive polymer the mucin glycoproteins and the polymer chains can 
diffuse across the interface and adhesive forces are developed due to interaction 
and entanglement of the chains. 
 
However, no study really proves this theory. For a dry solid formulation the 
often rapidly developing mucoadhesive forces cannot just be explained by this 
theory, since the interpenetration of polymer chains can only occur when the 
polymers are sufficiently hydrated. Here, the dehydration theory provides a 
more likely explanation for the initial adhesion. This theory means there is a 
movement of water from the mucosa into the polymer formulation resulting in 
the hydration of the polymer and a local dehydration in the mucus layer. The 
local lack of water in the mucus leads to a negative pressure and thus a 
“sucking” of the formulation to the mucosa [96, 97]. Figure 4 (adapted from 
[95]) shows an illustration of this theory.  
 
 
Figure 4. Schematic illustration of the different steps in the mucoadhesion process and the 
development of the adhesive joint according to the dehydration theory (adapted from [95]). 
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4.2.2 In vitro evaluation of mucoadhesion in correlation to osmotic 
pressure  
In order to achieve good mucoadhesive properties it is important to understand 
how excipients affect the mucoadhesive behaviour of a formulation. Water 
transport into the mucoadhesive tablet seems to be crucial for the adhesion of 
solid state formulations to the wet mucosa. Since a difference in the osmotic 
pressure is a driving force for water transport it should have a significant 
influence on the extent of mucoadhesion. Hence, excipients that alter the 
osmotic pressure in the formulation would also affect the adhesive behaviour of 
a tablet.  
 
The hypothesis that osmotic pressure differences can be correlated with the 
adhesiveness of dry hydrophilic tablets was therefore investigated in Paper I 
with tablets based on the hydrophilic polymer Carbopol®. Carbopol®, which is 
the trade-name for carbomer, was chosen since it is one of the best known 
mucoadhesives that is pharmaceutically approved. It consists of hydrophilic 
cross-linked polyacrylic acid (Figure 5) which easily swells and forms a gel 
when it comes into contact with water. This property might be the main reason 
for the extensive mucoadhesive behavior since the adhesiveness of Carbopol® 
tablets can directly be correlated to the amount of swelling (Paper I). Another 
theory of the mucoadhesive behavior of Carbopol® describes the phenomenon 
whereby carboxyl groups interact and orientate 
towards the mucosa and form hydrogen bonds 
[98]. Carbomers are commonly used as 
thickeners, suspending agents and emulsifying 
agents [99]. As Carbopol® is a hydrophilic 
swelling polymer it can also be used to modify 
the velocity of drug release from tablet 
formulations which was also of interest in this 
thesis (Paper III). 
 
Different parameters have been used to assess in vitro mucoadhesive properties 
including molecular interactions and the adhesive force. The latter was applied 
for the aim of the studies in Paper I, i.e. the force required for the detachment 
of a formulation was measured. Either tissues, mucin solutions or other systems 
that imitate a mucosa can be used to replicate a mucosal surface [100, 101]. 
Tissue samples might be the best alternative from a biological point of view, 
however, it is often hard to fix tissue samples in a way that makes a detachment 
of tablets possible and moreover, the reproducibility is often poor. Therefore, 
an agarose gel was used as a model surface in this work and Carbopol® tablets 
Figure 5. Structure of polyacrylic 
acid. 
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of 12 mm diameter served as a model formulation. Sodium chloride (NaCl) and 
mannitol were added in different concentrations to the agarose solution before 
the gels were made in order to modify the osmotic pressure difference between 
the gel and the tablet. To be able to keep the agarose gel in place during the 
adhesion measurements, they were directly manufactured in steel vessels. 
Force-displacement measurements were performed using a Texture Analyzer 
TA-HDi (Stable Micro Systems). The tablet was attached to the upper movable 
probe and after lowering it onto the model surface they were kept in contact at 
a constant force for a specified time. During the following detachment of the 
tablet in vertical direction the force required was recorded as a function of both 
time and distance (probe displacement). From the resulting force-time or force-
distance plot the maximum adhesive force (N) can be determined and if it is of 
interest the latter can also be used to determine the adhesive work (Nmm) from 
the area under the curve (AUC) as illustrated in Figure 6.  
 
 
Figure 6. Schematic drawing of the upper probe with the attached tablet which is lowered onto the 
agarose gel. The force required for the detachment of the tablet (the probe is raised again, as indicated 
by the arrow) is recorded as a function of the probe displacement and the time. From the data the 
adhesive force and the adhesive work can be obtained as illustrated in the force-distance graph. 
 
In all cases the swollen tablets were also re-weighed immediately after each run 
in order to measure the amount of water taken up by the tablet. The agarose 
surface was inspected after each measurement to ensure that the failure in the 
adhesive joint did not occur in the agarose gel. 
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4.3 Modified protein release from sublingual tablet 
formulations 
As mentioned above, tablets are the most prevalent solid dosage form. 
However, many people, especially children, have difficulties in swallowing a 
tablet which impedes patient compliance. Sublingual tablets against different 
diseases have therefore been developed during recent years in order to facilitate 
intake and increase patient compliance. Considering the benefits of sublingual 
immunization discussed in Chapter 3, it seems therefore interesting and 
beneficial to develop a sublingual vaccine tablet and the question is how the 
antigen should be released from such a formulation. An extended release would 
result in exposure of the antigen for a prolonged period of time which could 
probably be advantageous. However, all sublingual formulations containing 
low molecular APIs that are on the market are based on fast dissolving tablets 
and in contrast to the buccal route (which is the administration via the mucosa 
lining the cheeks) the use of extended release tablets (ER tablets) for sublingual 
administration seems to be quiet unexplored [91]. Therefore it was of interest to 
investigate the use of hydrophilic matrix tablets as extended release delivery 
systems for sublingual vaccination and compare their properties with an 
immediate release tablet (IR tablet).  
 
4.3.1 Excipients to control the release profile 
The basis of a pharmaceutical tablet is often a substance that serves as a 
bulking agent. In order to obtain a fast dissolving tablet that releases the API 
more or less immediately disintegrating excipients with the ability to rapidly 
break the tablet into small fragments can be incorporated in the tablet powder 
blend [92]. If a longer exposition is desired different technologies are available 
to design a tablet with an extended release of the API. A very common method 
is the embedding of the API in a slowly eroding matrix of hydrophilic 
polymers. Upon contact with water a hydration of the polymer occurs leading 
to gel formation. As mentioned in the previous chapter, many of these 
polymers also provide mucoadhesive properties [95] which would be 
advantageous for a sublingual tablet. The release rate of the API from a 
hydrophilic matrix tablet is affected by the dissolution and diffusion of the API, 
the diffusion path length and the rate of matrix erosion [102]. In the case of 
vaccine tablets the antigenic material is normally of macromolecular nature. 
The diffusion of the API will thus be extremely slow so that erosion will be the 
most likely release mechanism.  
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In order to examine the ability to evoke immune responses with sublingually 
administered tablets different formulations were prepared and characterized in 
vitro and subsequently tested in mice (Paper III). Since the main aim was to 
investigate if a slow releasing formulation could provide advantages over an IR 
tablet by providing an exposure of small antigen amounts over a prolonged 
time, three different ER tablets were prepared containing OVA as a soluble 
model protein antigen and the formulations were compared with an IR tablet 
formulation. The matrices of the three ER tablets were composed of (i) 
hydroxypropyl methylcellulose (HPMC), (ii) HPMC mixed with mannitol and 
(iii) Carbopol®; the IR tablet contained a mixture of microcrystalline cellulose 
(MCC) and lactose. Lactose is a widely used pharmaceutical excipient that can 
be used as a tablet and capsule filler or diluent and among the different 
disintegrants that are available MCC was chosen for that study since it is a 
widely used excipient in oral formulations [99]. HPMC is one of the most 
commonly used hydrophilic polymers for release-rate controlling swellable 
matrix tablets and consists of a cellulose ether substituted with methoxy and 
hydroxypropoxy groups (Figure 7). Like Carbopol® it is also used in other 
pharmaceutical contents as a thickening or stabilizing agent or for coatings 
[99]. All experiments in this work are based on HPMC 90SH 100 000 (Ph. Eur. 
type 2208) which has a methoxyl content (w/w) of 22-24 % and a 
hydroxypropoxyl content (w/w) of 8-12 % and a viscosity grade of 100 000 
mPa*s [103]. Mannitol, which is otherwise most often used as a bulking agent, 
has been found to increase the rate 
of water transport into tablets and 
thus the dissolution rate of the tablet 
[99, 104]. It is a hexahydric alcohol 
with a high solubility (aqueous 
solubility 240 mg/ml) and was used 
to modify the release of protein from 
HPMC tablets so that different 
release profiles were obtained.  
 
Since all formulations were aimed to be tested in vivo on mice and it was found 
that HPMC tablets did not adhere sufficiently under the murine tongue, all 
tablets for the in vivo examinations were manufactured as two-layer tablets 
with a matrix layer containing the antigen and a mucoadhesive layer composed 
of pure Carbopol® (Figure 8). The tablets for the in vitro characterizations were 
made without this second mucoadhesive layer. 
 
Figure 7. Structure of hydroxylpropyl 
methylcellulose (HPMC).
R= -H, -CH3, -CH2CH(CH3)OH
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Mucoadhesive layer (Carbopol®)
Tablet matrix containing OVA as model protein antigen
 
Figure 8. Illustration of a two-layer tablet consisting of a mucoadhesive layer and a protein releasing 
layer. 
 
4.3.2 Characterization of protein release 
Different standardized methods are available to study the release from tablets, 
a.o. by the United States Pharmacopeia (USP). However, no standard method 
exists that provides a good correlation for the in vivo situation of sublingually 
delivered tablets. All protein release characterizations in Paper III were 
therefore performed with a standard procedure for orally administered tablets 
using a modified variant of the USP II dissolution model. A stirring paddle was 
put in the release medium and instead of having the tablet free in the vessel it 
was fixed in a stationary non-rotating basket above the paddle (Figure 9). This 
modification leads to more reproducible hydrodynamic conditions [105] and 
the tablet cannot adhere to the vessel or float in the bottom or at the surface of 
the medium, so that hydration occurs from all sides at all times. When this 
method is used it is however important to ensure that the tablet does not swell 
to such an extent that its size becomes larger than the basket, since this would 
most likely lead to a disruption of the gel layer. 
 
a b
 
Figure 9. (a) Photograph of a release study setup using a temperate dissolution bath with USP vessels. 
(b) Schematic illustration of a USP vessel with tablet basket. 
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4.3.3 Protein analysis with Bradford Assay 
In order to determine the concentration of protein in the samples containing 
OVA within the protein release study, the widely used Bradford Assay was 
used. This spectroscopic assay allows a fast determination with high sensitivity 
and specificity for proteins and can, depending on the protein concentration, 
even be performed with small sample volumes. The method is based on a 
complex reaction between protein and the dye Coomassie blue (CB). CB has 
been used as a colorimetric reagent for the detection and quantitation of protein 
since 1976 [106]. Depending on the pH in the surrounding medium CB can 
occur in three different forms (anionic, cationic or neutral) with different 
UV/Vis absorption spectra. Thus, the chemical environment influences the 
UV/Vis absorption spectrum and the maximum level of absorption shifts to 
different wavelengths and reveals different colours under changing conditions 
(Figure 10) [107].  
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Figure 10. Structure of Coomassie blue dye and equilibrium of the different states with corresponding 
absorption maxima according to [107]. 
 
In its cationic form, i.e. under acidic conditions, CB is able to bind to protein 
which results in a spectral shift from a reddish/brown form to a blue-coloured 
form. This increasing UV/Vis absorption can be measured at 595 nm and the 
obtained absorption can be related to the protein concentration using a recorded 
standard curve [106, 107]. However, based on recently reported perturbations 
by polyethylene glycol [108] one has to consider that polymers in the sample 
can disturb the analysis, by disturbing both the reaction and the absorption 
measurement. For the use of the assay in the present work an investigation of 
possible disturbances by the pharmaceutical excipients that were co-released 
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with the protein was necessary (Paper II). Possible disturbances caused by 
polymers are light scattering or an interaction with either the dye or the protein. 
For the examination of possible interferences of the excipients with the 
Bradford method UV/VIS spectra were recorded instead of measuring the 
absorption at the fixed wavelength of 595 nm as specified in the Assay Kit. 
Pure excipient samples as well as protein samples in the presence of the 
excipients were investigated and compared with each other. 
 
4.4 Drying of antigenic material 
Antigenic material is often available or produced in the liquid state and needs 
to be converted into the dry state if it is to be used in a solid dosage form. In 
many cases it might be a challenge to find an appropriate drying process which 
does not affect the immunogenicity of the antigen. Different drying techniques 
are conceivable such as conventional oven drying, spray-drying, freeze-drying 
or spray-freeze drying. However, the choice of the drying method as well as the 
physico-chemical parameters during the drying process will influence the 
product properties. Spray-drying and freeze-drying are the most commonly 
used techniques for protein drying in the pharmaceutical industry [109], 
whereas other methods are more common on a research scale. Different 
parameters are important for the choice of a suitable method, such as cost 
efficacy and the desired route of administration.  
 
In this work freeze-drying was chosen as the drying tool for the production of a 
dry bacterial whole-cell vaccine using V. cholerae as model vaccine where 
different conditions were evaluated (Paper IV). This drying technique is 
especially advantageous for heat-labile materials and was chosen due to several 
advantages discussed below that outweigh the disadvantageous long and cost 
consuming freeze-drying process.  
 
4.4.1 Freeze-drying of killed whole-cell Vibrio cholerae 
The principle of the freeze-drying process is based on the direct sublimation of 
frozen water, i.e. a phase transition from the solid ice state to the gas state [110, 
111]. Prior to drying, the sample is therefore frozen so that ice crystals start to 
grow. This can be done in an external freezer or directly in the freeze-dryer 
where it is possible to control the freezing rate. In the present work the initial 
freezing-step of V. cholerae formulations was performed in an external freezer 
at – 70 °C overnight and the samples were subsequently put into the freeze-
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dryer. To start the freeze-drying process the pressure in the drying chamber was 
lowered below the triple point of water to initiate sublimation. Since 
sublimation is an endothermic process, the shelf temperature was raised in 
order to provide additional energy and the drying was performed at a shelf 
temperature of -5 °C and a pressure of 0.78 mbar. After the primary drying it is 
possible to apply a second drying step where the temperature is further raised 
so that unfrozen water that is adsorbed to the solid ice-free matrix is desorbed. 
This is mostly done to lower the residual moisture content in the dried material 
and was not performed in the present study.  
 
4.4.2 Advantages and challenges in freeze-drying of antigenic material 
As mentioned above, the liquid is removed at low temperatures and in the 
freeze-dried state chemical or physical degradation is often inhibited or at least 
decelerated, thus resulting in a better stability of the product. The obtained 
porous cake has a large surface area that provides a fast dissolution, which 
might be advantageous if the product should be rapidly re-suspended, for 
example for immediate oral intake or injection. An additional advantage for 
parenteral formulations is the fact that sterile products are easy to obtain [109]. 
Furthermore, freeze-drying can also be used for the manufacturing of fast 
dissolving tablets [112].  
 
The freeze-drying process includes however a variety of stresses that can affect 
the stability of proteins. At high freezing rates, smaller ice crystals and thus 
larger ice-water interfaces are formed, which can lead to surface-induced 
protein destabilization. Some buffer components tend to crystallize during 
freezing which can lead to a pH change and thus to conditions that might not be 
suitable for the material to be dried [111]. The dehydration process also 
removes hydrogen-bonded water and thus parts of the protein hydration shell 
[113]. When bacteria are dried this can lead to membrane damage and loss of 
function [114, 115]. Furthermore, as the sample becomes more concentrated 
during the water removal the possibility for interactions increases, and thus the 
risk for protein or bacterial aggregation. Such interaction can become a 
problem in the production of a dried antigen for a solid state vaccine. 
Regarding long-term stability of freeze-dried protein formulations, storage 
temperature, glass transition temperature and residual moisture content are 
important factors. Generally, one can say that the higher the storage 
temperature, the lower is the stability of a freeze-dried protein. The glass 
transition temperature, Tg, is defined as the temperature where a transition 
between the glassy (solid-like) and the rubbery (liquid-like) state occurs [113]. 
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Storage above Tg of the dried preparation might result in cake collapse and can 
lead to a rapid crystallization of the amorphous components resulting in an 
accelerated instability of the protein [113]. The residual moisture content after 
freeze-drying is also of importance for long term stability. Water can either 
provide a reaction medium or react directly as a reactant with the dried 
material. The residual water can also act as a plasticizer and thus reduce the Tg 
of the formulation. The higher the residual moisture content, the more Tg 
decreases which in turn often lowers the stability of the product [116, 117].  
 
4.4.3 Excipients for stabilization of bacterial antigens during freeze-drying 
To meet the mentioned challenges associated with the freeze-drying process 
most freeze-dried protein products typically contain a buffer besides the active 
component, bulking agents such as mannitol or lactose to provide good cake 
properties and in the case of protein formulations stabilizing excipients. The 
stabilization capability of excipients needs to be examined in two stages: during 
the freeze-drying process and during long-term storage. The main stabilization 
mechanisms by excipients involve the formation of an amorphous glassy state, 
replacement of the removed water and hydrogen bonding with the protein. 
Non-reducing sugars are commonly used as stabilizing excipients for dried 
protein formulations since they can form hydrogen bonds with proteins. 
Different sugars can be differently efficient depending on the product to be 
dried and often a concentration-dependent stabilization efficacy is observed 
[113].  
 
In this work focus was put on process stabilization, where the effect of three 
different excipients (Figure 11) on bacterial aggregation and antigen structure 
preservation was investigated (paper IV). Two common stabilizers, sucrose and 
trehalose, were investigated, but even the less effective substance mannitol was 
included in the study since mannitol is known to be a good bulking agent in 
lyophilized materials [99]. Sucrose, which is composed of the monosaccharides 
glucose and fructose, is otherwise frequently used as syrup in oral 
pharmaceutical formulations, as tablet or capsule diluent, in sugar coatings, as a 
granulating agent or to increase viscosity [99]. Trehalose, which is a 
disaccharide consisting of two glucose units, is less common in these contexts, 
maybe due to higher costs. The fact that both sucrose and trehalose are non-
reducing sugars, since neither of the rings in the molecules can be opened to 
form aldehyde groups in solution, is one reason for their use as stabilizers in the 
freeze-drying of biological materials [114]. In the literature trehalose is often 
seen as the first choice stabilizer, but for each material the best one has to be 
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investigated individually. Since sucrose is the more common excipient in 
pharmaceutical formulations and it is much cheaper than trehalose, we wanted 
to examine and compare the capability of both sugars to provide stabilization of 
killed whole-cell bacteria during freeze-drying. Since both the type of excipient 
and the concentration play a role for the stabilizing capacity, all three 
excipients were examined in three different concentrations (0.25 mg/ml, 2.5 
mg/ml and 25 mg/ml). 
  
 
Figure 11. Structures of the excipients that were investigated in this thesis as stabilizers during freeze-
drying of killed whole-cell bacteria. (a) mannitol, (b) sucrose, (c) trehalose. 
 
4.5 Characterization of freeze-dried material 
Freeze-dried samples can be characterized by different techniques both in the 
dry state and after dissolution or re-suspension. In this work the aim was to find 
stabilizing excipients that can avoid bacterial aggregation and maintain the 
functionality of the antigenic structures, the lipopolysaccharides (LPS) on the 
surface of V. cholerae. The latter could easily be investigated with re-
suspended samples by ELISA. The extent of aggregation of the bacteria could 
successfully be visualized by confocal microscopy. 
 
4.5.1 Confocal microscopy for evaluation of bacterial aggregation 
Confocal microscopy (CM) is an optical imaging technique used to capture 
images of fluorescent samples by excitation of the sample and detection of the 
emitted signals. In contrast to a traditional wide-field fluorescence microscope 
where fluorophores through the whole sample are excited at once and signals 
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are collected from the sample and areas outside the plane of focus, the CM 
technique uses point illumination and collects fluorescent signals emitted from 
the sample via a pinhole aperture to eliminate background signals [118, 119]. 
This provides an increased optical resolution and contrast so that the images are 
not so blurry. A further advantage of the confocal microscope is that a series of 
optical sections at different depths can be used to reconstruct 3D images of the 
sample. The depth to which samples can be visualized depends on the 
transparency of the sample, the excitation wavelength and the objective [118]. 
The most commonly used type of confocal microscope, which was also used in 
this work, is a laser scanning confocal microscope (LSCM), i.e. a focused laser 
beam scans the sample and the emitted fluorescent signals are detected by a 
photo detector. Different immunofluorescence reagents or staining dyes can be 
used to study biological structures or functions. In order to make a visualization 
of the freeze-dried V. cholerae bacteria in Paper IV possible, the re-suspended 
samples were mixed with the biological stain safranin. This coloring agent has 
positive charges which can bind to negatively charged molecules in a biological 
sample, as for example the nuclei or the surface of bacteria. The samples to be 
investigated were excited at 488 nm and the emission was detected in the 
wavelength range 500 – 700 nm. 
 
4.5.2 ELISA for functionality test of LPS antigen 
An “inhibition” ELISA, or in the literature also called “competitive” ELISA, 
was used for the detection of intact surface LPS. This ELISA variant is used if 
two matching antibodies are not available [89]. Excess antibody is incubated 
with an antigen-containing sample, in this case with the re-suspended freeze-
dried samples, and the mixture is then added to an antigen-coated plate to 
which the remaining free antibody binds. The better LPS is preserved in the 
sample, the less free antibody is available for binding on the plate and by 
comparing with a reference the maintenance of the LPS structures can be 
estimated. 
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Chapter 5 
OUTCOME OF RESEARCH 
 
In order to design solid dosage forms that are suitable for mucosal vaccination 
knowledge of crucial formulation properties and an understanding of how to 
obtain them are required. Figure 12 shows an overview of the key issues 
investigated in this thesis which will be discussed in the following chapters: 
 
 
Figure 12. Overview of the investigations in this thesis concerning the influence of excipients in the 
design of solid dosage forms for mucosal immunization. 
 
5.1 Investigations on mucoadhesion in relation to previous 
work 
 
The first thoughts of this work concerned the development of a sticky solid 
formulation for vaccine delivery to the sublingual mucosa and the question 
arose whether an ER tablet could be a benefit for the efficacy of such a vaccine. 
Hydrophilic polymers can have mucoadhesive properties and are commonly 
used as a matrix for ER tablets. The well-known mucoadhesive and hydrophilic 
polymer Carbopol® was chosen as a starting point for the development of a 
sublingual mucoadhesive vaccine tablet. 
As described in Chapter 4 one mechanism that is discussed in the literature as 
the responsible one for the mucoadhesive behavior of hydrophilic polymer 
tablets is their ability to swell, i.e. to take up huge amounts of water upon 
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contact with a wet surface [96, 120]. The water uptake by the tablet results in a 
local lack of water in the mucosa generating an under pressure so that a suction 
force is developed [97]. A difference in the osmotic pressure is one main 
driving force for the movement of water and therefore the hypothesis was 
raised that osmotic pressure might have a direct impact on the adhesive force.  
 
To study this relationship between osmotic pressure and adhesive force a model 
system was used where the osmotic pressure could be tuned. The weight 
increase of the tablet after the adhesion measurement was used as a parameter 
for the amount of water transported into the tablet. The first investigations dealt 
with the impact of the time of contact between the tablet and the agarose model 
surface on the water uptake by the tablets in correlation with the developed 
adhesive force. In Figure 13 it can be seen that forces of up to 0.7 N could be 
detected which is comparable to the gravity force of a tablet with a 200-fold 
higher weight than the dry tablet. Both the adhesive force and the tablet weight 
increased with a prolonged contact time. An interesting observation was that 
the initial distinct increase of the adhesive force leveled out while the water 
gain by the tablet continuously increased, which indicates that the tablet swells 
at a relatively constant rate and that a water transport from the agarose gel into 
the tablet occurs at all times. An explanation for this could be that the adhesive 
force develops mostly in the initial time phase by a negative pressure due to an 
initial local lack of water and when water starts to flow within the agarose gel 
to equal out this imbalance, 
the negative pressure does not 
increase as much as before so 
that the effect of the water 
flow into the tablet levels out. 
However, these are only 
speculative interpretations and 
more mechanistic 
investigations would be 
required in order to explain 
this phenomenon in more 
detail. 
 
For the following investigations on the influence of osmotic pressure 
differences on the adhesive force a contact time of 180 s was chosen since the 
effect of the adhesion time had leveled out at that point in time. The osmotic 
pressure of the agarose gel was increased by the addition of different amounts 
of solute (0 – 1.0 M), which in turn decreased the osmotic pressure difference 
Figure 13. Impact of contact time on the water gain and 
the adhesive force of Carbopol® tablets. Each data point 
represents the mean (± SD) of five replicate 
measurements.
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between the agarose gel and the tablet. Thus, a decrease in the water flow into 
the tablet and hence a lowered adhesive force was expected according to the 
proposed hypothesis. Indeed, this could be confirmed both when NaCl or 
mannitol was added to the agarose gel as can be seen in Figure 14, where 
increasing additive concentrations result in decreasing adhesive forces. 
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Figure 14. Effect of NaCl and mannitol addition (a) on the water uptake by Carbopol® tablets 
measured as weight gain and (b) on the adhesive force measured as the maximum force required for the 
detachment of the tablet from an agarose surface. Each data point represents the mean (± SD) of five 
replicate measurements. 
 
Similar observations can be found in other published studies. Lejoyeux et al. 
[121] found for example that and an addition of NaCl and calcium chloride 
(CaCl2) to a buffer solution surrounding Carbopol® tablets that were attached to 
sublingual and vaginal tissue samples resulted in lower adhesive forces of the 
tablets to the tissues, where CaCl2 had a stronger effect than NaCl. The authors 
of that study discuss these results in terms of ionic shielding effects on the 
polyacrylic acid molecules by the divalent ions. However, this explanation does 
not hold in the case of mannitol since it has a very low shielding effect. In 
contrast, the theory evaluated in this work can be applied to the results by 
Lejoyeux et al; CaCl2 has a higher van’t Hoff factor than NaCl and thus 
decreases the osmotic pressure difference more which leads to a stronger 
decrease in the adhesive forces. Another study by Mortazavi and Smart showed 
that anionic polymers dehydrate a mucus gel more than neutral polymers [96], 
which can also be explained by the different osmotic pressures caused by the 
polymers. Similar observations were made when pure Carbopol® and HPMC 
tablets were compared by us with the mucoadhesion test method used in this 
work. The weight gain by neutral HPMC tablets was lower than by Carbopol® 
tablets. The measured adhesive forces showed also slight differences, where the 
HPMC tablets were less adhesive than the Carbopol® tablets, so that even here 
a correlation between osmotic pressure and adhesive force can be speculated 
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(Table 1). The same results were obtained with the method used in the study by 
Lejoyeux et al. where the positively charged Carbopol® showed a higher 
adhesiveness than HPMC [121]. 
 
Table 1. Influence of the polymer type on water uptake (measured as tablet weight gain) and adhesive 
force (measured as the force required to detach a 12 mm-tablet from an agarose surface). 
Polymer Weight gain (mg)  
(± SD) 
Adhesive force (N)  
(± SD) 
Carbopol® 974-P NF 38.7 (1.1) 0.8 (0.1) 
HPMC 90 SH 100 000 28.2 (1.1) 0.7 (0.1) 
 
 
Taken together, the results from this study as well as data from the literature 
show that osmotic pressure is an important parameter for the adhesiveness of 
dry tablets based on hydrophilic polymers. Both the composition of the 
mucosal tissue and the excipients in a dry formulation can alter the osmotic 
pressure. Thus, the influence of excipients on the mucoadhesiveness of a tablet 
should be considered in the design of such formulations. Since Carbopol® is 
known to be a good mucoadhesive polymer and the high charge density creates 
a high osmotic pressure in the formulation, Carbopol® was chosen as the 
mucoadhesive component to adhere tablets sublingually in mice. 
 
5.2 Modified protein release from tablet formulations 
All samples from the protein release studies were analyzed using the Bradford 
method. When the fractions of released protein were calculated, it was 
observed that the total amount of protein released from the Carbopol® matrix 
tablets after complete dissolution of the tablets was not in accordance with the 
actual amount incorporated in the tablets. Thus, the analysis method was put 
into question and standard curves of OVA in the absence and the presence of 
Carbopol® were detected. Remarkable differences in the absorption at 595 nm, 
the monitoring wavelength of the Bradford Assay, were found where all OVA 
samples had a higher absorbance as compared to the equivalent samples 
without Carbopol® (Figure 15).  
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Figure 15. Absorbance of OVA-Coomassie Blue samples at the monitoring wavelength of the 
Bradford Assay (595 nm) as a function of the protein concentration in the absence of polymer (filled 
squares) and in the presence of 100 µg/ml Carbopol® (open triangles). 
 
5.3 Development of an analysis method for protein 
quantification in the presence of pharmaceutical excipients 
As a consequence of the detected disturbances by Carbopol® in the analysis of 
OVA samples by the Bradford method, a general evaluation of the method in 
the presence of excipients was performed. Three different hydrophilic polymers 
that might be of interest for mucoadhesive formulations were investigated: 
positively charged Carbopol®, neutral HPMC and negatively charged Chitosan. 
In addition, all other excipients used in the formulations of the release study 
were also tested for their influence on the detection of OVA with the Bradford 
assay in order to be sure that all protein determinations were performed 
correctly. In addition to measurements at the monitoring wavelength of the 
assay wavelength scans in the range of 350 – 850 nm were recorded in order to 
make the finding of disturbances easier.  
 
No disturbances were found by HPMC, mannitol, lactose or MCC. In contrast, 
the presence of Chitosan or Carbopol® changed the absorption spectra of the 
CB dye as it can be seen in Figure 16. 
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Figure 16. Absorption spectra of the Bradford reagent solution: in absence of protein and polymer 
(continuous black), in presence of 10 µg/ml OVA (blue line), in presence of 100 µg/ml Carbopol® (red 
line) and in presence of 5 µg/ml Chitosan (green line). 
 
The presence of Chitosan resulted in a shift of the main peak at 645 nm to 
lower wavelengths similar to that obtained when OVA is present, which 
indicated an interaction of Chitosan with the CB dye. The presence of 
Carbopol® did not lead to a spectral shift of the main peak but instead to an 
increase in the absorbance. This increase was detected at all wavelengths 
including those where CB does not absorb, i.e. the spectrum of the CB dye was 
shifted upwards without any changes in the shape. Since this effect was also 
observed in a solution of the same pH in the absence of CB dye (Paper II) the 
disturbance by Carbopol® was interpreted as a turbidity effect caused by small 
Carbopol® aggregates due to the low pH of the reagent solution. 
In the case of Chitosan further investigations showed a concentration-
dependent effect on the absorbance where higher concentrations of the polymer 
resulted in an increased absorbance. This observation further indicated that 
chitosan interacts with the dye. Since the interaction of Chitosan and the CB 
dye disturbs the CB spectrum at the monitoring wavelength of the Bradford 
Assay in such a concentration-dependent manner, the monitored absorbance of 
protein samples will differ with different Chitosan concentrations and it is 
difficult to make corrections for this perturbation. In the case of Carbopol® 
however only scattering perturbations and no indications for an interaction with 
the dye were found. This scattering effect was also found to be concentration-
dependent where the absorbance caused by scattering increased with increasing 
polymer concentrations. Since the scattering contribution of Carbopol® could 
be related to the amplitude at 850 nm where CB itself has no absorbance, the 
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absorbance at 850 nm could be used to make corrections for the disturbance by 
subtracting the value from the value measured at 595 nm. Since light scattering 
increases with decreasing wavelengths, the absorption at 850 nm had to be 
multiplied with a constant that takes this effect into account and a value of 1.5 
was found to be appropriate under Bradford conditions: 
 
Acorr (595 nm) = A (595 nm) – 1.5 · A (850 nm).   
 
Figure 17 shows OVA standard curves recorded in the presence of different 
Carbopol® concentrations after correction by this method. The absorbance 
increased with increasing OVA concentration and the same absorbance was 
measured in samples with equal OVA concentrations regardless of the 
Carbopol® concentration, showing that the correction method works. 
 
0 5 10 15 20 25
0.0
0.3
0.4
0.5
0.6
0.7
0.8
0.9
Carbopol concentration
 0 g/ml
 10 g/ml
 50 g/ml
 100 g/ml
 150 g/mlA
bs
or
ba
nc
e 
at
 5
95
 n
m
OVA concentration (g/ml)  
Figure 17. Absorbance at the monitoring wavelength of the Bradford assay (595 nm) of OVA-CB dye 
samples containing different concentrations of Carbopol® after correction for the scattering effect by 
Carbopol® according to the described method.  
 
5.4 In vitro and in vivo evaluations of controlled release 
tablets for sublingual immunization 
With the gained knowledge from the evaluation of the Bradford method and the 
possibility to correct for perturbations by co-released Carbopol® all samples 
from the OVA release study could be analyzed correctly. As desired, the three 
ER tablets released OVA during differently prolonged times, whereas all 
protein was immediately released from the MCC/lactose formulation. The 
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entire protein amount incorporated in the latter formulation could already be 
detected at the first sampling time point of 5 minutes (Figure 18).  
 
The Carbopol® matrix tablet dissolved as expected very slowly and hence after 
one day just under 60 % of the total amount were released. Both HPMC 
formulations showed a prolonged release whereof the formulation containing 
40 % mannitol had a steeper release profile and almost 90 % of the total 
amount of protein was already released after 10 hours; in contrast to the 
formulation consisting solely of HPMC which had released all protein after 
approximately one day. Thus, the tablets showed different protein release 
profiles and were subsequently tested in mice. 
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Figure 18. Release of OVA at 100 rpm paddle stirring rate from tablet formulations containing OVA in 
a matrix of lactose/MCC (open triangles), Carbopol® 974 P-NF (crosses), HPMC 90 SH 100000 (filled 
triangles) and HPMC 90 SH 100000/mannitol (open squares). Each data point represents the mean (± 
SD) of three different tablet preparations. 
 
After the characterization of the release profiles it was examined if it is possible 
to evoke an immune response with a sublingually administered tablet 
formulation and how the release rate affects the elicited immune response. The 
analyzed serum and intestinal samples from the sublingual immunizations in 
mice showed that it was indeed possible to evoke immune responses with a 
tablet formulation (Figure 19).  
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Figure 19. Serum and intestinal anti-OVA antibody responses in mice immunized sublingually with 
ovalbumin (OVA) and CT as adjuvant. Doses of 250 µg OVA and 7.5 µg CT were given on days 0 + 1 
and 16. Five groups of five mice each received tablet formulations. The reference group was 
immunized with a solution of OVA in PBS. (a) Serum IgG responses and (b) standardized small 
intestine (SI) IgA responses were measured against OVA by ELISA and are expressed as log10 
antibody titres (GM ± SEM). Asterisks denote significant differences ( ** P < 0.01, *** P < 0.001, ns 
= non-significant) compared to the reference group. 
 
With the IR tablet systemic and mucosal antibody levels not significantly lower 
than those obtained with the OVA solution could be elicited. However, only 
poor responses were evoked with the three ER tablets; the antibody levels in all 
three groups were significantly lower, both in serum and intestinal samples. 
Interestingly, even if not significant, the differences in the antibody levels 
between the three groups that had received ER tablets had the same tendency as 
the differences in the release profiles: the lowest antibody levels were measured 
in mice that had been immunized with Carbopol® tablets (slowest ER tablet) 
whereas the highest levels were detected in mice that had received the 
HPMC/mannitol formulation (fastest releasing ER tablet). 
 
These results gave rise to the two interpretations that a prolonged release might 
be unsuitable for sublingual immunization and that the slower the release of the 
antigen, the lower the evoked immune response. The latter is, however, more a 
speculation and more significant data are required for proving this 
interpretation. It is also important to consider that it is only valid for the model 
system used in this study that ER tablets are not resulting in any advantages for 
sublingual immunization since there are several factors that could have 
influenced the outcome of the present investigations. Since only small amounts 
of antigen are presented to the immune system at each point of time, the 
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immune response might depend on the total amount in the formulations and the 
type of antigen. In addition, the fact that CT was not co-released but given at 
once when the sublingual tablets were administered might have had an impact 
on the immune responses since the earlier observed time-dependent adjuvant 
effect of CT by Lycke et al. [78] was even observed in the investigations of 
Paper III. Furthermore, it is possible that the ER tablets were not kept at the 
administration site until erosion was complete. Even if the adhesion of test 
formulations could be confirmed for four hours in several mice, there is, of 
course, still a risk that some mice swallowed the gelled tablets or gel pieces.  
 
5.5 Freeze-drying of killed whole-cell bacteria  
If one wants to produce a solid vaccine for mucosal administration, finding of a 
drying process for the manufacturing of dry antigen is crucial. In the work in 
Paper IV killed whole-cell V. cholerae strain JS 1569 and the commercially 
available vaccine DukoralTM were used as model vaccines for the evaluation of 
stabilizing excipients during freeze-drying of a bacterial vaccine. The in vitro 
characterization of freeze-dried formalin-killed V. cholerae O1 strain JS 1569 
showed clear differences between the samples depending on how the bacteria 
were freeze-dried. The presence of a stabilizing agent was required both to 
avoid aggregation and to preserve the LPS antigen functionality on the surface 
of the bacteria and the stabilizing capacity was dependent on the type of 
stabilizer and the concentration. The results of the performed LPS inhibition 
ELISA are summarized in Table 2 and indicate a remarkable loss of the 
functionality of the surface LPS, the main protective antigen of V. cholera, in 
the absence of any potential stabilizer (only 37 % LPS recovery). The presence 
of stabilizer concentrations of 0.25 mg/ml or 2.5 mg/ml resulted in a better LPS 
recovery, but still no sample was above a 70 % recovery rate. This was even 
the case in the presence of 25 mg/ml mannitol or trehalose. In contrast, when 
25 mg/ml sucrose was added the LPS functionality could sufficiently be 
maintained, as can be seen in the LPS mean recovery rate of 89 %, which was 
not significantly lower as compared to the untreated bacteria suspension (p > 
0.05). Thus, these results indicated that only the latter condition could preserve 
the important LPS surface antigen of V. cholerae during freeze-drying to a 
satisfactory extent.  
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Table 2. Preservation of V. cholerae O1 surface LPS after freeze-drying (FD) with and without 
excipients of different concentrations. The samples were re-suspended in PBS and the LPS recovery 
was determined by LPS inhibition ELISA.  
Formulation mg/ml LPS recovery (% ± SE) ANOVA
Untreated n.a. 100  12 n.a.
FD n.a. 37  3 P  0.001
FD + mannitol
0.25 52  12 P  0.001
2.5 61  3 P  0.05
25 60  4 P  0.01
FD + sucrose
0.25 36  3 P  0.001
2.5 62  1 P  0.01
25 89  10 P  0.05
FD + trehalose
0.25 28  1 P  0.001
2.5 63  5 P  0.01
25 70  7 P  0.05
 
 
In the following characterizations by confocal microscopy all samples 
containing excipient at the highest tested concentration (25 mg/ml) were 
analyzed and compared with an untreated suspension (Figure 20a) in order to 
study eventual changes in the morphology, size or aggregation. Sucrose even 
showed promising results here. An image of a re-suspended freeze-dried 
sample without any excipient for stabilization is shown in Figure 20b which 
clearly shows large and densely packed bacterial aggregates of partly over 
10 µm diameter. Much smaller and less dense, but still numerous aggregates 
were found in the samples freeze-dried with mannitol (Figure 20c). In contrast, 
V. cholerae freeze-dried with sucrose and even those with trehalose showed no 
changes in the morphology and no aggregates could be found by confocal 
microscopy. 
 
a b
c d
e
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Figure 20. Images of formalin-killed JS 1569 V. cholerae (suspended in PBS) taken by confocal 
microscopy. (a) untreated, (b) freeze-dried, (c) freeze-dried with 25 mg/ml mannitol, (d) freeze-dried 
with 25 mg/ml sucrose and (e) freeze-dried with 25 mg/ml trehalose. The x- and y-axes of the z-stack 
images are scaled in 5 µm units and the dimensions are 33.81 µm x 33.81 µm in x- and y- direction and 
vary between 2.75 and 6.52 µm in z-direction depending on the properties of the sample. 
 
From the in vitro characterizations it could be concluded that sucrose and 
possibly trehalose at a concentration of 25 mg/ml seem to sufficiently stabilize 
V. cholerae during freeze-drying. Since all excipients at lower concentrations 
failed as stabilizing agents, the in vivo evaluations in BALB/c mice were only 
performed with freeze-dried samples of JS 1569 containing either 25 mg/ml of 
excipient or no excipient. The ability to elicit systemic and mucosal immune 
responses after peroral administration was investigated by comparing these 
formulations with untreated JS 1569 suspension. The results are shown below 
in Figure 21.  
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Figure 21. Serum and intestinal anti-O1 LPS antibody responses in mice immunized perorally with 
formalin-killed V. cholerae strain JS 1569. All groups of mice (four mice in each group) were 
immunized with doses containing 5 x 108 bacteria on days 0 and 2, 13 and 15, 41 and 43. Four groups 
received bacteria that had been freeze-dried (FD) in the absence or in the presence of an excipient 
(mannitol, sucrose or trehalose) and one group received untreated bacteria (reference). (a) Serum 
IgG+IgM responses and (b) standardized fecal pellet (FP) IgA responses were measured against O1 
LPS by ELISA and are expressed as log10 antibody titres (GM±SE). The mean antibody level of sham-
immunized mice (control group) was significantly lower than the reference group (*** P < 0.001) 
whereas no significant differences to the reference group were found in all other mice. 
 
The antibody titres of the negative control group originate from previous 
experiments and are included to show that no responses can be evoked by 
sham-immunization with PBS alone. All groups of mice except for the control 
group developed both serum and intestinal anti-LPS antibodies. Variations 
between the effects of the excipients were found, as anticipated from the in 
vitro evaluations, however, the differences were not as distinct as in vitro. JS 
1569 freeze-dried with mannitol elicited, as expected from the in vitro results, 
immune responses with lower systemic IgG+IgM antibody levels as compared 
to the untreated reference. The IgA levels detected in the small intestine were 
also lower in these mice. Freeze-dried JS 1569 stabilized with sucrose or 
trehalose had almost the same immunogenicity as can be seen in the similar 
systemic and mucosal responses. However, since slightly higher IgG+IgM and 
IgA antibody levels were measured in mice that had been immunized with 
freeze-dried JS 1569 stabilized by sucrose, the overall conclusion from the in 
vitro and in vivo data was that sucrose seems to provide the best stabilizing 
properties of all tested excipients during the drying process. Surprisingly, 
antibody levels comparable to the reference group were also found in mice that 
had received JS 1569 freeze-dried without any excipient. This formulation was 
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not expected to have a good immunogenicity according to all in vitro results. A 
speculative explanation could be that the recognition of bacterial surface LPS is 
not the only important property for an in vivo effect. It is also possible that an 
aggregation of the bacteria hampers the LPS recognition by the ELISA method, 
whereas the immune system is able to recognize the antigen, for example by 
processing and breaking up the aggregates. However, if the latter would be the 
case, even JS 1569 freeze-dried with mannitol should be as immunogenic as the 
freeze-dried preparation without excipient. 
 
Summarizing both the in vitro and in vivo characterizations of freeze-dried JS 
1569 formulations it could be concluded that sucrose was a promising stabilizer 
throughout all experiments. Trehalose showed a similar potential, however, this 
excipient is more expensive than sucrose and also less common in 
pharmaceutical products on the market, so that it provides no benefits over 
sucrose. According to the in vitro results, mannitol provided a poorer 
stabilizing capacity with regard to both bacterial aggregation and LPC 
maintenance and even the in vivo immunizations indicated the lowest ability to 
maintain the immunogenicity of JS 1569 during freeze-drying. Based on these 
considerations, the freeze-drying process was applied to the commercially 
available oral cholera vaccine DukoralTM, with either no stabilizer or with 
25 mg/ml sucrose as the stabilizing excipient and the freeze-dried vaccine was 
compared with the original vaccine suspension in peroral immunizations in 
BALB/c mice. Since the efficacy of DukoralTM is connected with both 
antibacterial and antitoxic IgA antibodies [70], sera and intestinal samples were 
analyzed for both anti-O1 LPS and anti-rCTB antibodies. In addition to FP 
estimates the intestinal antibody response was even measured in tissue extracts 
of the small intestine, since any possible impact of naturally excreted IgA from 
the liver via bile to the intestinal lumen [122] is avoided in those samples so 
that they provide direct evidence of the site-specific local production of IgA in 
the gut. 
 
The antibody levels of all immunized mice are shown in Figure 22. The 
negative control data are as in Figure 21 taken from earlier experiments. All 
immunized mice elicited antibody titres significantly higher than this control. 
As already observed in the peroral immunizations with freeze-dried JS 1569, 
no significant differences were found between the groups. For the antitoxic 
responses similar antibody titres were expected both in sera and intestinal 
samples since it could be confirmed by a GM1 ELISA that CTB maintains its 
binding capacity during the freeze-drying process (data not shown). Compared 
to untreated DukoralTM, vaccine freeze-dried with sucrose evoked as observed 
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with the single JS 1569 strain, similar and not significantly lower antibacterial 
antibody levels. Only slightly lower antibacterial antibody levels were 
measured in mice that had been immunized with freeze-dried DukoralTM 
without sucrose stabilization, so that the surprisingly good immunogenicity of 
freeze-dried killed whole-cell V. cholerae in the absence of any excipient was 
confirmed even with the mixture of the different V. cholerae strains present in 
the DukoralTM vaccine.  
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Figure 22. Antibacterial and antitoxic responses in mice immunized perorally with DukoralTM vaccine. 
All groups of mice (seven animals per group) were immunized with doses containing 5 x 108 bacteria 
in three rounds on days 0 and 1, 14 and 15, 27 and 28. Two groups received DukoralTM formulations 
that had been freeze-dried in the absence and in the presence of sucrose, respectively, and the reference 
group received untreated vaccine. Immune responses were measured against O1 LPS (filled bars) and 
rCTB (striped bars) by ELISA and are expressed as log10 antibody titres (GM ± SE). (a) Serum 
IgG+IgM responses, (b) standardized small intestine (SI) IgA responses and (c) standardized fecal 
pellet (FP) IgA responses. 
 
Although no significant differences in the immunogenicity of the freeze-dried 
formulations were found regardless of the presence or absence of any excipient, 
one would not prefer a vaccine consisting of aggregated bacteria with 
obviously poor LPS antigen activity found in a LPS inhibition ELISA. The in 
vivo results of this study give raise to different questions to be solved, but it can 
anyhow be concluded that the use of excipients should be considered for a 
stabilization of killed whole-cell bacteria during freeze-drying and that sucrose 
might be a potential candidate.  
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Chapter 6 
CONCLUDING REMARKS 
 
The use of solid dosage forms for vaccines has so far been less common since 
most vaccines are injected as a liquid. However, there is a great need to 
develop delivery systems for non-invasive mucosal vaccines against infections 
starting at a mucosal surface, where injectable vaccines are not sufficiently 
protective. Solid dosage forms would provide a variety of advantages over 
conventional injectable vaccines and research is therefore needed to define 
important properties of suitable delivery systems for an efficient presentation of 
protective antigen to the mucosal immune system. Since the performance of a 
formulation is dependent on the right excipients in the formulation, the 
emphasis in the studies presented in this thesis was put on the influence of 
excipients associated with different aspects concerning the design of mucosal 
vaccine delivery systems.  
 
Figure 23 summarizes the key findings of the different areas discussed in the 
previous chapters: 
 
Characterization
of antigen 
structure
preservation
Mucoadhesion Protein release Freeze‐drying of
bacterial antigen
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Bradford protein 
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of impact on 
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Best immune 
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formulation
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Correction of
disturbance by 
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Figure 23. Overview of the outcome of the investigations in this thesis concerning the role of 
excipients. 
 
It was found that osmotic pressure is an important factor for the mucoadhesive 
properties of tablets that swell upon contact with water. Since the nature of 
different excipients will reveal different osmotic pressures in a formulation, it 
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might be important to keep these findings in mind if a good mucoadhesiveness 
is desired. In vivo investigations in mice showed that tablets can be kept at the 
sublingual mucosa for several hours using the mucoadhesive polymer 
Carbopol® and that it is possible to efficiently deliver antigen formulated in a 
solid dosage form. The use of hydrophilic matrix tablets, which often also 
provide mucoadhesive properties, did not seem to be advantageous as 
sublingual vaccine tablets against enteric diseases since they release the antigen 
too slowly in order to be able to induce a sufficient immune response in the gut. 
Excipients that lead to an immediate release of the antigen should instead take 
preference. A fast dissolving sublingual tablet formulation is also most likely to 
be accepted by the patient than one that has to be kept under the tongue over a 
longer period of time. On the way to the findings of the release study a very 
commonly used analytical method for protein determination, the Bradford 
Assay, was evaluated and it could be concluded that the presence of charged 
excipients in protein samples can disturb the determination. For the 
disturbances caused by Carbopol® a correction method could be developed. 
The results of the assay evaluation show not only the effect of different 
pharmaceutically relevant polymers, but moreover also how important it is to 
question traditional analytic tools that are always mentioned as fast and simple 
in the literature but might carry a risk for false results if one is not observant. 
The freeze-drying study showed that it is possible to produce a freeze-dried 
cholera vaccine formulation based on killed whole-cell bacteria if the bacteria 
are stabilized by sucrose so that no loss in the antigen functionality and the 
immunogenicity of the vaccine occurs.  
 
Given the huge number of aspects that are important in the design of an 
efficient mucosal vaccine formulation, a lot of work remains to be done. The 
fact that the studies in this thesis have shown that it is possible to evoke 
mucosal and systemic immune responses with a mucosal solid state 
formulation if the right excipients are used motivates a continued research 
within this interdisciplinary field. Especially the positive results with the IR 
tablet in the sublingual immunization study indicate great possibilities due to 
the ability of the sublingual mucosa to disseminate immune responses to 
various mucosal tissues. Clinical trials are ongoing on several mucosal vaccines 
including the improvement of both existing vaccines and new vaccines [33] and 
in my opinion the success of these vaccines will depend on a proper 
formulation work where the findings presented here can provide helpful 
knowledge. 
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Chapter 7 
FUTURE OUTLOOK 
 
The results presented in this thesis give rise to several ideas for related future 
studies that would be interesting to perform: 
 
In spite of the efficacy of DukoralTM the vaccine is relatively cost intensive to 
produce. This is due to different V. cholerae strains and two different 
inactivation methods so that the development of new improved cholera 
vaccines is still ongoing. It would thus be interesting to apply the present 
findings on such future cholera vaccines, but even on other future vaccines 
against bacterial gastrointestinal infections as those caused by ETEC or 
Helicobacter pylori. Combining the findings in Paper III that an immediate 
release of antigen might be most effective in sublingual vaccination, the freeze-
drying conditions of Paper IV and the fact that freeze-dried materials 
commonly are easy to dissolve with the knowledge that sublingual 
immunization can induce strong responses in the gut, the design of a sublingual 
vaccine tablet against enteric infections based on a freeze-dried formulation of 
killed whole-cell bacteria seems possible. For the development of such a 
formulation it would be required to investigate the influence of pressure during 
the compression of the tablet on the morphology and immunogenicity of the 
bacteria and how excipients can be used to provide stabilization during the 
processing if required. Regarding stabilization it is of course also of interest to 
perform long-term stability studies of these solid state vaccines and what 
excipients one should choose in order to achieve the desired stability 
properties.  
 
Besides the application of the present findings on different “real” antigens it 
would also be interesting to investigate the use of other drying techniques. 
Since freeze-drying gives more dried cakes rather than powders, spray-freeze-
drying is an interesting alternative. I would further like to study the effect of the 
release rate in mucosal immunization with other antigens and at mucosal 
administration sites other than the sublingual. It remains of course also to be 
seen to what extent the gained knowledge is applicable to humans where 
features such as the bacterial and enzymatic environment, the nutritional status 
or the physiological conditions might differ from the murine model.  
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